Infectious pathogens are becoming increasingly resistant to the armoury of available medicines we rely on to treat them. New treatments and drug regimens that could be used are therefore needed. Use of vaccines will also be important because they reduce the need for treatments by preventing people from getting ill in the first place.
Researchers in this field include:
Drug development
- Professor Darius Armstrong-James: Antifungal chemotherapies and immunotherapies
- Dr Anna Barnard: Novel and selective inhibitors of therapeutically important protein-protein interactions.
- Dr Frances Davies: Optimising the care of patients with multi-drug resistant organisms
- Professor Francis Drobniewski: Treatments of respiratory infections, especially TB and mycobacterial diseases
- Dr Andy Edward and Professor Ed Tate: Small molecules and screening facility
- Professor Mark Gilchrist: Assessing and optimising therapeutics and care
- Professor Anthony Gordon: Conducting randomised clinical trials in sepsis
- Dr Alex McCarthy: Development of new approaches to tackle virulent E. coli
- Dr Julie McDonald: Gut microbiota and colonisation resistance
- Professor Alexandra Porter: Inhaled delivery of antibiotics
- Professor James Seddon: New drugs and new therapies for prevention and treatment of MDR-TB in children
- Dr Anand Shah: Improving outcome in pulmonary fungal lung disease
- Dr Claire Waddington: Impact of vaccines and vaccination on AMR
- Professor Ramesh Wigneshweraraj: Bacterial viruses (phages) to tackle drug-resistant infections.
- Professor Rob Wilkinson: Combination therapies for resistance for people with HIV/TB
Vaccine design and development
- Professor Robin Shattock: Self-amplifying RNA vaccines
- Professor Francis Drobniewski: Treatments of respiratory infections, especially TB and mycobacterial diseases and vaccine hesitancy
- Professor Graham Cooke: Development of novel vaccination strategies through use of models of human infection
- Professor Peter Openshaw: Human experimental challenge to accelerate vaccine development, crucial to prevent infections and therefore antibiotic use.
- Professor Faith Osier: Malaria vaccines
- Professor Shiranee Sriskandan: Novel approaches to developing vaccines for bacterial infections
- Professor Mariagrazia Pizza: Pathogenesis and vaccines on antimicrobial resistant pathogens.
- Dr John Tregoning: Vaccines for respiratory pathogens, including RSV, influenza and A. baumannii
- Dr Matthew Siggins: Lymphatic-homing bacterial vaccine vectors
